Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 28, 2021 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in the Benzinga Healthcare Small Cap Conference

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
September 09, 2021 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in Three September 2021 Investor Conferences

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
August 16, 2021 16:01 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights

Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record Rolling NDA submission for CUTX-101 for the treatment of Menkes disease expected to begin in...
June 30, 2021 08:00 ET | Source: Fortress Biotech, Inc.

Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea

NEW YORK and SCOTTSDALE, Ariz., June 30, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today...
June 01, 2021 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in Three June 2021 Virtual Investor Conferences

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
May 19, 2021 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Announces Webinar Hosted by ROTH Capital Partners Featuring Partner Company Journey Medical Corporation

NEW YORK and SCOTTSDALE, Ariz., May 19, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and...
May 17, 2021 07:00 ET | Source: Fortress Biotech, Inc.

REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of...
May 16, 2021 16:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of...
May 10, 2021 06:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe

Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney...
April 07, 2021 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...